Abstracts tagged "pain"

Abstract Number: 0413 • ACR Convergence 2023
Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gábor Sütő², Gábor Kumánovics³, József Kun⁴, Péter Urbán⁵, Attila Gyenesei⁵, Panna Királyhidi⁶, Georg Schett⁷, György Nagy⁸ and Zsuzsanna Helyes⁹, ¹Department of Pharmacology and Pharmacotherapy, University of Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Budapest, Hungary, ²Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ³Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary, ⁴Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Budapest, Hungary, ⁵Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁶Department of Genetics, Cell- and Immunobiology, Semmelweis University School of Medicine, Budapest, Hungary, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, Semmelweis University School of Medicine; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ⁹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Pécs, Hungary; National Laboratory for Drug Research and Development, Pécs, Hungary
Background/Purpose: Despite novel treatment strategies in rheumatoid arthritis (RA), approximately 20-30% of patients remain symptomatic. The EULAR definition of difficult-to-treat (D2T) RA has recently been…
Abstract Number: 0865 • ACR Convergence 2023
Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy
Caifeng Deng¹, Yongbing Xiao², Xuan Zhao¹, Hui Li², Yuxiao Chen¹, Chao Zeng² and Guanghua Lei², ¹Xiangya Hospital, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Unbalanced M1/M2 polarization of synovial macrophages plays vital roles in the symptomatic and structural progression of osteoarthritis (OA). The accumulation of intracellular reactive oxygen…
Abstract Number: 1290 • ACR Convergence 2023
Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis
Katie McMenamin¹, Kristin Wipfler², Austin Wheeler³, Grant Cannon⁴, K Wysham⁵, Brian Sauer⁶, Bryant England³, Kaleb Michaud³, Ted R Mikuls⁷ and Joshua Baker⁸, ¹Boston University, Boston, MA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
Abstract Number: 1812 • ACR Convergence 2023
Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Laura Daniel¹, Alyson Dickson², Puran Nepal¹, Otis Wilson³, Adriana Hung², Dale Plummer³, William Dupont³, Katherine Murray³, C. Michael Stein², Wayne Ray³ and Cecilia Chung⁴, ¹University of Miami, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴University of Miami, Miami, FL
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the FDA for the treatment of different forms of chronic pain. Because of its adrenergic activity,…
Abstract Number: 1982 • ACR Convergence 2023
Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis
Terence O'Neill¹, Matthew Parkes¹, Michael Bowes², Richard Hodgson¹ and David Felson³, ¹University of Manchester, Manchester, United Kingdom, ²Imorphics, Manchester, United Kingdom, ³Boston University, Boston, MA
Background/Purpose: There are currently no licensed therapies which reduce progression of knee OA. Current therapies focus on reducing pain, have limited effect, and some have…
Abstract Number: 2525 • ACR Convergence 2023
Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain
Samantha Price¹, Karin Silbernagel², David Felson³, Joshua Stefanik⁴ and Patrick Corrigan¹, ¹Saint Louis University, St. Louis, MO, ²University of Delaware, Avondale, PA, ³Boston University, Boston, MA, ⁴Northeastern University, Boston, MA
Background/Purpose: Knee pain is one of the most common types of joint pain leading to disability, limited physical activity, and reduced quality of life. While…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
Abstract Number: 0867 • ACR Convergence 2023
Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
Ravi Krishnan¹, Catherine Stapledon², Christian Reiter², Stewart Ryan³, Sebastien Bauquier³ and Thierry Beths³, ¹Paradigm Biopharmaceuticals, Adelaide, Australia, ²Paradigm Biopharmaceuticals, Melbourne, Australia, ³U-Vet Werribee Animal Hospital, University of Melbourne, Melbourne, Australia
Background/Purpose: Pentosan Polysulfate sodium (PPS) is a semi-synthetic polysaccharide and a glycosaminoglycan mimetic. The multiple actions of PPS involve anti-inflammatory effects via inhibition of NF-κB;…
Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
John Lampa¹, Dan Nordstrom², Ronald van Vollenhoven³, Merete Hetland⁴, Espen A Haavardsholm⁵, Mikkel Østergaard⁶, Anna Rudin⁷, Marte Schrumpf Heiberg⁵, Michael Nurmohamed³, Bjorn Gudbjornsson⁸, Kristina Lend⁹, Kim Hørslev-Petersen¹⁰, Tuulikki Sokka-Isler¹¹, Gerdur Maria Grondal¹², Simon Krabbe¹³, Joakim Lindqvist¹⁴, Anna-Karin Hultgård Ekwall¹⁵, Daniel Glinatsi¹⁶, Meliha Kapetanovic¹⁷, Cidem Gentline¹⁴, Anna-Birgitte Aga¹⁸, Heikki Relas², Tove Lorenzen¹⁹, Giovanni Cagnotto²⁰, Johan Back²¹, Oliver Hendricks²², Bas Dijkshoorn²³, Kajsa Öberg²⁴, Maud-Kristine Aga Ljoså²⁵, Eli Brodin²⁶, Hanne Merete Lindegaard²⁷, Annika Söderbergh²⁸, Milad Rizk²⁹, Alf Kastbom³⁰, Per Larsson³¹, Line Uhrenholt³², Søren Just³³, David J Stevens³⁴, Trine B Laurberg³⁵, Gunnstein Bakland³⁶, Inge Olsen³⁷, Joseph Sexton¹⁸ and Till Uhlig¹⁸, ¹Stockholm County, Hãsselby, Sweden, ²Helsinki University Hospital, Helsinki, Finland, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰University of Southern Denmark, Odense, Denmark, ¹¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹³Herlev-Gentofte University Hospital, Herlev, Denmark, ¹⁴Karolinska University Hospital, Stockholm, Sweden, ¹⁵Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ¹⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ¹⁷Lund University and Skåne University Hospital, Lund, Sweden, ¹⁸Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Silkeborg University Hospital, Silkeborg, Denmark, ²⁰Skåne University Hospital, Lund, Sweden, ²¹Uppsala University Hospital, Uppsala, Sweden, ²²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²³Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²⁴Falu Hospital, Falun, Sweden, ²⁵Ålesund Hospital, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Odense Hospital, Odense, Denmark, ²⁸Örebro University Hospital, Örebro, Sweden, ²⁹Västmanlands Hospital Västerås, Västerås, Sweden, ³⁰Linköping University, Linköping, Sweden, ³¹Academic Specialist Center, Stockholm, Sweden, ³²Aalborg University Hospital, Aalborg, Denmark, ³³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ³⁴St. Olavs Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…
Abstract Number: 1819 • ACR Convergence 2023
Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data
Max Lyon, Carlos Ramirez Medina, Elinor Davies and Meghna Jani, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Prescription opioids for non-cancer pain in the UK have increased considerably over the past two decades, alongside a rise in associated harms. Despite the…
Abstract Number: 1990 • ACR Convergence 2023
Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis
Ehyun Kim¹, Tuhina Neogi², Benjamin Senderling¹, Mary Gheller¹, Lee Marinko¹, Michael LaValley³, Lukas Adamowicz⁴, Pirinka Georgiev⁴, Charmaine Demanuele⁴, Paul Wacnik⁴ and Deepak Kumar¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Pfizer Inc., Cambridge, MA
Background/Purpose: Movement-evoked pain (MEP), i.e., pain that appears with or is made worse by movement, is a common complaint in people with knee osteoarthritis (OA).…
Abstract Number: 2565 • ACR Convergence 2023
The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021
Titilola Falasinnu¹, Di Lu² and Matthew Baker³, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford University, Menlo Park, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
Abstract Number: 0434 • ACR Convergence 2023
Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
Mai Yamashita¹, Takaichi Okano¹, Iku Shirasugi¹, Hirotaka Yamada¹, Keisuke Nishimura¹, Sho Sendo¹, Yo Ueda¹, Toshihisa Maeda², Shinya Hayashi², Wataru Yamamoto³, Akira Onishi⁴, Kosaku Murakami⁵, Hideyuki Shiba⁶, Kenichiro Hata⁶, Kohei Tsujimoto⁷, Kosuke Ebina⁸, Yonsu Son⁹, Naofumi Yoshida⁹, Ryota Hara¹⁰, Ryu Watanabe¹¹, Motomu Hashimoto¹¹, Ryosuke Kuroda² and Jun Saegusa¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ⁷Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Toyonaka, Osaka, Japan, ⁸Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Toyonaka,Osaka, Japan, ⁹First Department of Internal Medicine, Kansai Medical University, Osaka, Hirakata, Japan, ¹⁰Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan, ¹¹Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Background/Purpose: Non-inflammatory pain (NIP) is one of the remaining issues in rheumatoid arthritis (RA), and some previous studies suggest that 10-20% of patients with RA…
Abstract Number: 0876 • ACR Convergence 2023
Metabolomic Analysis Reveals Associations Between Calcium Crystals and Metabolites in Osteoarthritic Synovial Tissue
Nathan Argel¹, Sina Stücker², Adnan Cutuk³, Robert Meyer³, Nancy Lane⁴, Jessica Bertrand², Monica Guma³ and Jessica Murillo-Saich¹, ¹Department of Medicine, University of California San Diego, La Jolla, CA, ²Department of Orthopaedic Surgery, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany, ³San Diego VA Healthcare Service, La Jolla, CA, ⁴University of California, Hillsborough, CA
Background/Purpose: Emerging research suggests that synovial inflammation and metabolic alterations are involved in the progression of osteoarthritis (OA). Additionally, the presence of calcium-containing crystals (CC),…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…

« Previous Page
1
…
7
8
9
10
11
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].